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SUPPLEMENTARY NOTES
ABSTRACT
Treating breast cancer that has metastasized to the central nervous system remains a formidable challenge due to, 1) its high malignancy, 2) the difficulty in differentiating between tumor and healthy brain tissue, 3) the sensitivity of normal brain tissue to the toxicities of current therapies, 4) intrinsic cellular resistance of BMBC cells to chemotherapeutic drugs, and 5) the bloodbrain barrier's (BBB) ability to prevent the passage of extrinsic substances such as drugs and contrast agents. Our aim is to develop magnetic contrast agents and targeted siRNA therapies capable of overcoming the blood brain barrier and to aid in both the diagnosis and treatment brain metastatic breast cancer. Magnetic nanoparticles with high susceptibility have been developed. These nanoparticles have been characterized to be monodispersed are working to engineer a nanovector that will aid in addressing the major challenges associated with the diagnosis and treatment of BMBC. The major components of the nanovector include a Fe3O4 superparamagnetic nanoparticle (NP) core and a shell comprised of a copolymer of polyethylene glycol (PEG)-grafted chitosan (C)-polyethyleneimine (P), or CP. The tumor targeting peptide, chlorotoxin (CTX), and siRNA (designed to knockdown the pro metastasis gene MENA) also are conjugated to the NP polymer overcoat.
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Introduction
The aim of this research project is to develop a new generation of nucleic acid-carrier nanovectors that can pass biological barriers and non-invasively diagnosis, stage, treat and treat brain metastatic breast cancer. Despite advances made in breast cancer diagnosis and therapy, the prognosis for patients with brain metastasis remains dismal. Currently, only 20% of patients with breast cancer that has metastasized to the brain survive more than a year, and the incidence of this disease appears to be rising (1, 2) . Treating breast cancer that has metastasized to the central nervous system (CNS) remains a formidable challenge due to: 1) its high malignancy, 2) the difficulty in differentiating between tumor and healthy brain tissue, 3) the sensitivity of normal brain tissue to the toxicities of current therapies, 4) intrinsic cellular resistance of metastasized breast cancer cells to chemotherapeutic drugs, and 5) the blood brain barrier's (BBB) ability to prevent the passage of extrinsic substances such as drugs and contrast agents (3) (4) (5) . Use of superparamagnetic nanoparticles conjugated with targeting or therapeutic agents, combined with magnetic resonance imaging (MRI), has been recognized as a potential approach for early breast cancer detection and treatment. In this first year of this project we have focused on developing a nanovector that can address these challenges in the diagnosis and treatment of brain metastatic breast cancer. The major components of this nanovector include a Fe 3 O 4 nanoparticle (NP) core and a shell comprised of a copolymer of polyethylene glycol (PEG)-grafted chitosan (C)-polyethyleneimine (PEI), or C-PEG-PEI. The tumor targeting peptide, chlorotoxin (CTX), and siRNA against the protein Mena is conjugated to the polymer overcoat of the NP. Mena is a protein which is recognized as member of the Ena/VASP family proteins that function to regulate cell motility through actin polymerization (6) (7) (8) . Mena is shown to be upregulated in breast cancer cells and is a key mediator of cell metastasis (6) . In this naovector system, the combination of chitosan and PEG form a biocompatible coating on the iron oxide core, stabilizing the strructure from agglomeration. The PEI protects siRNA from degradation by nucleases and facilitates proper intracellular trafficking of nanovector by promoting "endosomal escape". CTX (36-amino acids) is chosen because of its strong selective affinity for metastatic breast cancer cells. The MRI detectable nanovector system we aim to develop is comprised of a superparamagnetic iron oxide nanoparticle core (NP) and a shell of a biodegradable polymer PEG-grafted chitosan (CP), which is then subsequently modified with PEI to promote endosomal escape, siRNA designed to silence pro metastatic genes, and CTX, a peptide that specifically binds breast cancer (9) . The CTX is a peptide that has been shown to effectively target metastatic tumor cells, and promote nanoparticle permeability across the BBB (10) through interaction with Annexin A2 receptors upregulated on endothelial cells of the neovasculature (11) . We have termed this fully assembled nanovector system NPCP-siRNA-CTX. During this year 1 reporting period (Months 1-4) we devoted significant effort towards the development of siRNA sequences that can be grafted on to our base chitosan-g-PEG coated iron oxide nanoparticle system. We specifically, have been able to foster a productive relationship with AXOlabs (Kulmbach, Germany), a world leader in the manufacturing of potent and robust oligonucleotides to provide us with siRNA oligos that we can graft onto our nanoparticles. Through discussions with there scientists we developed siRNA sequences that are specific for silencing the following reporter genes GFP and Luc. We also worked with their scientists to develop potent pan species siRNA sequence that can silence AHA1, housekeeping gene expressed by all cells in mice ( Figure 1 ) so that we could better monitor potential off target effects in healthy tissue compared to specific silencing in cancer cells. Finally, for our therapeutic gene of interest MENA and its invasive isoform MENA-INV we synthesized and screened 6 different sequences of siRNA in order to identify one sequence that was effective at silencing both.
Development of siRNA for covalent attachment To accomplish the covalent attachment chemistry we commercially procured siRNA designed to knockdown luciferase, GFP expression, or house keeping gene AHA1. For reporter sequences we contracted out AXO labs who aided us to screen a number of sequences and finally provided to us optimized sequences which These siRNA molecules where prepared with 5'thiol modification on sense strands and (fluorophore) modification on the antisense strand. The thiol modification was used to create a covalent linkage to the nanoparticle coating, and the fluorphore provided a means for monitoring of siRNA delivery to brain tumor cells. Using a commercial transfection reagents such lipofectamine RNAi MAX (Life Technologies, Carlsbad, CA) we evaluated a number siRNA sequences and identified the sequence below to be most effective in down regulating the expression of GFP and Luc in breast cancer cells (4T1-GFP-Luc, and MDA-MB231-GFP-Luc).
siRNA sequences (against genes of interest) have been obtained from AXOlabs. AXOlabs has devised produces siRNA sequences using proprietary technology enables production of siRNA that is carefully designed to minimize off-target potential and off-target microRNA type potential (12) . siRNA have been synthesized and evaluate to ensure high potency (IC50 in vitro in the range 1-100(500) pM) in order to prevent saturation of RISC complex when dosing effective quantities of siRNA. Chemical modifications have been introduced to stabilize siRNA for future in vivo applications, and reduce off-target potential of sense strand and minimize immune response.
Based on qRT PCR analysis we determined that this sequence was effective in down regulating GFP expression >90%.
Luc siRNA sequencesiLuc sense: 5' Fluorophore (Cy5 or Cy5.5.)-5'-CUUACGCUGAGUACUUCGATT-3', antisense: 5' Th (Thiol, or DBCO)-5'-UCGAAGUACUCAGCGUAAGTT-3
Based on qRT PCR analysis we determined that this sequence was effective in down regulating GFP expression >90%.
Similarly, we evaluated the potency and specificity of siRNA sequences designed against AHA1 AHA1 siRNA sequence:
We also synthesized and screened 6 different sequences of siRNA designed to silence MENA and its invasive isoform MENA-INV. These sequences where designed with the goal of identifying a single sequence that is able to silence both MENA and MENA-INV. For screening of silencing we used MDA-MB231 that where transfected to overexpress MENA or MDA-MB231-MENA INV. For this experiment 6 different siRNA sequences where designed and synthesized (Table 1 ). These 6 sequences where then screened in vitro and evaluated using qPCR for relative silencing of gene expression. Our results indicate siRNA sequence 6 to be the most efficacious at silencing both MENA and MENA-INV ( Figure 2 ).
Task 1b. Synthesize NPCP-siRNA-CTX and validate tumor specificity in vitro (Months 1-12).
Synthesis of NPCP-siRNA-CTX nanovectors We developed a conjugation scheme for the synthesis of NPCP-siRNA-CTX ( Figure 3) . As illustrated the process includes four major steps, 1) CP copolymer coupling, 2) nanoparticle synthesis and subsequent modification with PEI, 3) Functionalization with CTX, and 4) incorporation of siRNA onto nanoparticle. In the development phase parameters such as nanoparticle core/hydrodynamic size, zeta potential, density of coating, and the quantity of siRNA / CTX incorporated, have each be evaluated and optimized as needed in order to improve the overall functionality of the nanovector.
To increase the water solubility of chitosan and improve the anti-fouling properties of the coating material, we synthesized chitosan-grafted-PEG (CP) copolymer by conjugating mPEG to the amine groups of chitosan. However, since one end of the mPEG molecule ends with methoxy group and the other end has a hydroxyl group, its activation is necessary before conjugation and formation of the copolymer. Therefore, hydroxyl groups of the mPEG were first oxidized in the presence of acetic anhydride and DMSO to PEG-aldehyde. Cation exchange chromatography was then used to remove unreacted PEG molecules purify a fraction of mono-PEGylated chitosan. The resulted fractions from each step were collected and their PEG percentages were determined using the UV spectroscopy method. The quantifications showed that the range of 0.5 to 1.2M NaCl (step II) corresponds to monoPEGylated chitosan copolymer with homogeneous composition and molecular structure. The fraction collected at steps I had PEG ratios considerably more than one and the other fraction (step III) has almost no PEG.
To verify the successful attachment of PEG to chitosan, we used 1H NMR analysis to confirm the presence of bonded PEG after purifications. NMR samples were prepared by dissolving lyophilized CP powder in 5% solution of DCl in D2O (Figure 4 a) . the specific peaks of the mPEG can be seen at 3.6 and 3.9ppm, which corresponds to methyl groups and ether bonds of the PEG. Furthermore, after conjugation, the H-1 and H-2 proton signals from chitosan shifted from 4.9 to 5.1 and from 3.2 to 3.4 ppm, respectively. These shifts correspond to the Nalkylation of chitosan after the reaction. The peak at 2.3 ppm is from the acetyl groups present in the structure of the chitosan. Other peaks of the saccharine backbone of chitosan were not well separated in the range of 3.6-4.5ppm, which is due to the overlapping of a more intense PEG peak. The peak at 4.7 ppm is also related to the D2O solvent used during the analysis. These results showed that PEG was covalently attached to the backbone of chitosan. FTIR spectroscopy was additionally used to evaluate the molecular structure of CP copolymer (Fig. 4 b) . The purified copolymer was lyophilized and analyzed after mixing with KBr at 1:100 weight ratios. The peak around 3400cm-1 corresponds to the OH stretching vibration band due to water molecules physically adsorbed to the polymer. The most characteristic peak of the chitosan is the absorbance band at 1000-1150 cm-1, corresponding to the deforming vibrations of -C-O-C-groups. The band absorbance at 1655 cm-1 is reported to be related to carbonyl of amide groups (C=O), and the bands at 1560 and 1590 cm-1 are corresponded to the primary and secondary amine groups. The observed characteristic peaks of the PEG block of the copolymer can be also listed as: νas(CH2) at 2910cm−1, νs(CH2) at 2853cm−1, δ(CH2) at 1445cm−1, T(CH2) at 1350 cm−1, ω(CH2) at 1282cm−1, ν(C-O) at 1241cm−1 and ω(-CH) at 947 cm−1. Peaks related to the aldehyde groups (ν (C=O) at 1695cm−1) were not found in the spectra of copolymer, showing all the aldehyde groups were bonded to chitosan. In conclusion, FTIR spectra were consistent with NMR spectra and suggesting the successful conjugation of PEG to chitosan.
NPCP was produced by the co-precipitation of Fe 2+ and Fe 3+ ions in the presence of the monoPEGylated copolymer. Polymer and iron ions solutions were mixed together at 40ºC and then ammonium hydroxide solution was added to this vigorously stirring mixture under inert conditions. The schematic illustrated in figure 3 outlines the key steps for the synthesis of NPCP. The first step of the synthesis reaction is preparation of a homogeneous polymer and iron ions solution. In this solution iron ions will complex with chitosan polymers through chelation interactions. Next, ammonium hydroxide is titrated in the solution and as the solutions pH is increased NP cores form in spatially confined copolymer matrix. In this reaction scheme the copolymer serves as a surfactant on the surface of the NPs to control the overall morphology, size and polydispersity of the produced NP's (13) . The thickness and density of the coating polymer plays an integral role on hydrodynamic size of produced NP's. To determine the optimal amount of surface coating molecules, four copolymer to iron molar ratios of 0.115, 0.172, 0.220 and 0.270 were used for in-situ synthesis and coating of the nanoparticles. A modified fluorescamine-based quantification methods was then used to determine the average number of the chitosan molecules on each individual nanoparticle. The number of the chitosan molecules is the same as the number of PEG molecules, since a mono-PEGylated copolymer was used as the coating. Fig. 5a shows that the average number of coating molecules increased 12-folds, when the polymer to iron molar ratio increased for only 2.5-folds. This result shows the higher efficiency of the coating reaction at higher ratios of the polymer, due to increased probability of the polymer-surface interaction at higher polymer concentrations. However, DLS measurements showed that the hydrodynamic size (Z-average) and PDI of the nanoparticles were very similar, distributed in narrow ranges of 35-45nm and 0.183-0.203 (Fig. 5b) . Zeta potential measurement showed that the surface charges of the nanoparticles were in the neutral range (Fig. 5c) .
Nanoparticles developed for biomedical applications should remain stable the biologically relevant solutions such as buffers and cell culture media. Here, 100µg of the NPCP prepared with varying degree of PEG molecules per NP were dispersed and incubated in 1 mL of Dulbecco's modified Eagle's medium (DMEM) with 10% of fetal bovine serum (FBS), Dulbecco's phosphate-buffered saline (PBS), and sodium bicarbonate buffer. The hydrodynamic size of the nanoparticles was measured with DLS method and the nanoparticles were considered unstable when their size grew to more than 250nm. The long-term stability of the nanoparticles in different biological media is shown in Figure 6 . When there are about 353 PEG molecules on each NP, no significant change in hydrodynamic size was observed for at least 2 weeks in all the media. With increasing the amount of the copolymer from 28 to 353 molecules per NP, the size of the NPCPs increased at least 3 to 5-folds in PBS and cell culture media and about 2 to 3 times in sodium bicarbonate solution. The stability improved when there were more protective PEG molecules on the surface of the nanoparticles.
The morphology and crystallographic structure of the iron oxide core determines its physical properties and surface characteristics. The nanoparticles where analyzed for morphology using HRTEM characterizations (Figure 7 ). Samples were prepared by depositing and vacuum drying of a drop of the diluted nanoparticle suspension on carbon coated copper grids (300 mesh). The general morphology and size distribution of the iron oxide core of the nanoparticles is shown in Figure 7a . The nanoparticles have a very well defined size distribution in the range of 5-8 nm. HRTEM analysis (Figure 7b) , shows the constructive interference of the diffracted beams related to the (311) family planes with inter-planar distance of 0.25 Å, confirming the crystalline nature of the iron oxide nanoparticles. Selected Area Electron Diffraction (SAED) pattern of nanoparticles (Fig. 7c) showed bright and sharp spots, arranged as individual rings correlated to the (200), (220), (311) and (400) family planes of the magnetite, respectively from inner rings to the further ones. The bright and clear dot pattern of the rings proves that the nanoparticles have a high degree of crystallinity. This suggests that the strong bonding between the polymer and surface of the nuclei does not limit the growth of the NPs and iron ions can effectively diffuse through the polymer interface to attach to the atomic ledges available on the surface of the oxide core.
Integration of CTX and siRNA onto nanovector We investigated a number of strategies for a covalent immobilization biomolecules siRNA, and CTX on to our nanoparticles. From our evaluations it is apparent that nanovectors synthesized through a covalent coupling scheme is significantly more stable and effective for targeting breast cancer cells. We synthesized a nanovector comprised of our base iron oxide nanoparticle coated with shell of Chitosan-g-PEG, which was subsequently modified with siRNA, and CTX both through covalent linkages. Post synthesis nanoparticles were modified with CTX and then siRNA was reacted to NP using the hetrobifunctional linker molecule m-Maleimidobenzoyl Nhydroxysuccinimide (MBS-1). MBS-1 carries an NHS portion that reacts with primary amines of chitosan on nanoparticle shell, and a maleimide moiety, which reacts with thiol groups of siRNA. The MBS-1 molecule is first reacted with NP-CTX at a 10,000 fold excess of MBS-1 molecules per NP in PBS/5mMM EDTA buffer pH 7.4 for 30 min. NP's are then rapidly purified through gel permeation chromatography to remove excess MBS-1 molecules. The thiol modified siRNA molecules are then mixed with MBS modified NP's at NP:siRNA (w:w) ratio of 10 and allowed to react for 1 hour. Using gel electrophoresis we where able to confirm the attachment of CTX ( Figure 8 ) and siRNA ( Figure 9 ) onto NPCP.
Characterization of preferential uptake of NPCP-siRNA-CTX by MMP2 expressing cells compared to non-MMP2 expressing control cells. The targeting specificity NP-siRNA conjugated with CTX was optimized and confirmed in vitro using breast cancer tumor cells. The preferential uptake of NP-CTX-siRNA nanovectors by MMP2 expressing cells was compared to control non-MMP2 expressing cells conjugates over a range of treatment doses. In these studies the fluorescence properties of siRNA was monitored using flow cytomtery to determine the relative internalization of siRNA through targeting. Cells where treated for 1.5 hours and then evaluated for mean fluorescence intensity using a Facs Canto (Benton Dickinson, Franklin Lakes, NJ) flow cytometer. As shown in Months 1-12) .
A pilot experiment was performed to compare GFP transgene silencing in an MMP-2 positive cell lines (C6/GFP+ and one MMP-2 negative MCF/GFP+ cell line were evaluated in this study ( Figure 11 ). In this experiment cells where treated with nanoparticles at a concentration of 20 µg of Fe/ml for two hours after which time cells were rinsed and media was replaced and incubated for 48 hours prior to analysis. The results show that for the MMP-2 expressing cells we do see improved silencing through CTX modification. However, concerning is that silencing was observed in control MCF7 cells in both CTX modified and unmodified versions of nanoparticles. Future optimization of nanoparticles maybe necessary to improve the specificity of silencing
KEY RESEARCH ACCOMPLISHMENTS:
• Developed siRNA sequences to silence GFP, Luc, AHA1, and MENA/MENA-INV (Task 1a)
• Developed a synthesis scheme for preparing NPCP-siRNA-CTX and validated tumor cell specificity in vitro (Task 1b) • Synthesized and validated NPCP-siRNA-CTX in vitro gene silencing in cancer cell lines (Task 1c)
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